72.83
price up icon2.77%   1.96
pre-market  시장 영업 전:  71.99   -0.84   -1.15%
loading
전일 마감가:
$70.87
열려 있는:
$71.08
하루 거래량:
8.03M
Relative Volume:
1.46
시가총액:
$112.93B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
29.25
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
+3.44%
1개월 성능:
+1.56%
6개월 성능:
+7.70%
1년 성능:
-5.13%
1일 변동 폭
Value
$70.60
$73.20
1주일 범위
Value
$69.97
$73.20
52주 변동 폭
Value
$61.24
$87.67

아스트라제네카 ADR Stock (AZN) Company Profile

Name
명칭
Astrazeneca PLC
Name
전화
44 20 3749 5000
Name
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
직원
61,100
Name
트위터
@AstraZeneca
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
AZN's Discussions on Twitter

AZN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
72.83 218.30B 54.98B 7.77B 9.14B 2.49

아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-15 개시 Exane BNP Paribas Outperform
2025-02-13 업그레이드 UBS Neutral → Buy
2025-02-12 개시 Morgan Stanley Overweight
2024-11-20 업그레이드 UBS Sell → Neutral
2024-11-06 업그레이드 Deutsche Bank Sell → Hold
2024-09-13 다운그레이드 Deutsche Bank Hold → Sell
2024-05-30 개시 Goldman Buy
2024-04-16 업그레이드 Deutsche Bank Sell → Hold
2024-02-08 다운그레이드 Deutsche Bank Hold → Sell
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Sell
2024-01-03 다운그레이드 Jefferies Buy → Hold
2023-12-18 개시 HSBC Securities Buy
2023-09-25 업그레이드 Jefferies Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-07-12 업그레이드 UBS Neutral → Buy
2023-07-05 다운그레이드 Deutsche Bank Buy → Hold
2023-04-11 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-01-05 개시 BMO Capital Markets Outperform
2022-09-15 다운그레이드 Credit Suisse Outperform → Neutral
2022-09-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-08-29 업그레이드 Argus Hold → Buy
2022-06-14 다운그레이드 UBS Buy → Neutral
2022-02-11 업그레이드 DZ Bank Sell → Hold
2021-12-07 다운그레이드 Jefferies Buy → Hold
2021-08-12 재개 JP Morgan Overweight
2021-04-12 다운그레이드 Argus Buy → Hold
2021-03-16 업그레이드 Jefferies Hold → Buy
2021-02-25 업그레이드 UBS Neutral → Buy
2021-01-15 개시 Deutsche Bank Buy
2020-12-07 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-11-30 업그레이드 UBS Sell → Neutral
2020-11-11 업그레이드 HSBC Securities Reduce → Hold
2020-09-29 개시 Berenberg Buy
2019-11-22 개시 SVB Leerink Outperform
2019-10-25 업그레이드 Liberum Hold → Buy
2019-04-02 다운그레이드 UBS Neutral → Sell
2019-02-05 개시 Exane BNP Paribas Outperform
2019-01-25 업그레이드 Shore Capital Hold → Buy
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2018-08-16 다운그레이드 Jefferies Buy → Hold
2018-03-19 업그레이드 Jefferies Hold → Buy
2018-02-06 재확인 Leerink Partners Mkt Perform
2018-02-05 재확인 Bernstein Outperform
2018-01-18 재확인 Leerink Partners Mkt Perform
2017-12-29 업그레이드 JP Morgan Neutral → Overweight
2017-10-16 업그레이드 Credit Suisse Neutral → Outperform
2017-09-25 업그레이드 Exane BNP Paribas Neutral → Outperform
2017-09-22 업그레이드 Bernstein Mkt Perform → Outperform
모두보기

아스트라제네카 ADR 주식(AZN)의 최신 뉴스

pulisher
04:43 AM

AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com

04:43 AM
pulisher
04:02 AM

AstraZeneca: camizestrant effective in breast cancer - marketscreener.com

04:02 AM
pulisher
12:10 PM

AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit

12:10 PM
pulisher
Jun 01, 2025

PRESS DIGEST- Financial TimesJune 2 - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg.com

Jun 01, 2025
pulisher
May 30, 2025

AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News

May 30, 2025
pulisher
May 30, 2025

AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters

May 30, 2025
pulisher
May 30, 2025

Danaher Partners With AstraZeneca to Support Precision Medicine - TradingView

May 30, 2025
pulisher
May 30, 2025

AstraZeneca - Britannica

May 30, 2025
pulisher
May 30, 2025

AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues

May 30, 2025
pulisher
May 30, 2025

Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance

May 30, 2025
pulisher
May 29, 2025

AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360

May 29, 2025
pulisher
May 29, 2025

Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Transcript : AstraZeneca PLCSpecial Call - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

AstraZeneca and Global Transparency - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Ethics and Compliance - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Nature - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Inclusion and diversity - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Community investment - AstraZeneca

May 28, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus

May 27, 2025
pulisher
May 27, 2025

AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN

May 27, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Gains EU Panel Support for Imfinzi in Bladder Cancer - GuruFocus

May 27, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Nears EU Approval for Imfinzi in Bladder Cance - GuruFocus

May 27, 2025
pulisher
May 27, 2025

AstraZeneca wins EU backing for Imfinzi in bladder cancer - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

AstraZeneca Gains Positive Opinion for Imfinzi's Bladder Cancer Indication in EU - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

AstraZeneca: CHMP gives positive opinion for Imfinzi - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

EU recommends AstraZeneca bladder cancer treatment for approval - Sharecast.com

May 27, 2025
pulisher
May 27, 2025

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer - DirectorsTalk Interviews

May 27, 2025
pulisher
May 27, 2025

AstraZeneca's Imfinzi Wins EU Approval Recommendation for Bladder Cancer - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

AstraZeneca Says Imfinzi Recommended In EU For Bladder Cancer - marketscreener.com

May 27, 2025
pulisher
May 26, 2025

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

AstraZeneca (AZN) Partners in Sweden's Largest AI Supercomputer Initiative | AZN Stock News - GuruFocus

May 26, 2025
pulisher
May 26, 2025

Gouty Arthritis Market Overall Study Report 2025-2032 | - openPR.com

May 26, 2025

아스트라제네카 ADR (AZN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
자본화:     |  볼륨(24시간):